Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENu CRO to Train Research Therapists for Phase IIb Psilocybin Trial
Psyence Biomed Partners with Fluence and iNGENu CRO to Train Research Therapists for Phase IIb Psilocybin Trial
Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin